192 related articles for article (PubMed ID: 33035598)
21. Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance.
Xu S; Scott CAB; Coleman RL; Tuomilehto J; Holman RR
J Diabetes; 2021 Oct; 13(10):817-826. PubMed ID: 33665904
[TBL] [Abstract][Full Text] [Related]
22. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
Standl E; Stevens SR; Armstrong PW; Buse JB; Chan JCN; Green JB; Lachin JM; Scheen A; Travert F; Van de Werf F; Peterson ED; Holman RR;
Diabetes Care; 2018 Mar; 41(3):596-603. PubMed ID: 29311155
[TBL] [Abstract][Full Text] [Related]
23. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Verma S; Sharma A; Zinman B; Ofstad AP; Fitchett D; Brueckmann M; Wanner C; Zwiener I; George JT; Inzucchi SE; Butler J; Mazer CD
Diabetes Obes Metab; 2020 Jul; 22(7):1141-1150. PubMed ID: 32227432
[TBL] [Abstract][Full Text] [Related]
24. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
Gheorghiade M; Böhm M; Greene SJ; Fonarow GC; Lewis EF; Zannad F; Solomon SD; Baschiera F; Botha J; Hua TA; Gimpelewicz CR; Jaumont X; Lesogor A; Maggioni AP;
JAMA; 2013 Mar; 309(11):1125-35. PubMed ID: 23478743
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial.
Freedman BL; Berg DD; Scirica BM; Bohula EA; Goodrich EL; Sabatine MS; Morrow DA; Bonaca MP
Clin Cardiol; 2022 Aug; 45(8):831-838. PubMed ID: 35855557
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
White WB; Kupfer S; Zannad F; Mehta CR; Wilson CA; Lei L; Bakris GL; Nissen SE; Cushman WC; Heller SR; Bergenstal RM; Fleck PR; Cannon CP;
Diabetes Care; 2016 Jul; 39(7):1267-73. PubMed ID: 27289121
[TBL] [Abstract][Full Text] [Related]
27. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.
Sinha B; Ghosal S
Diabetes Res Clin Pract; 2019 Apr; 150():8-16. PubMed ID: 30794833
[TBL] [Abstract][Full Text] [Related]
28. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis.
Qiu M; Ding L; Zhou H
Medicine (Baltimore); 2021 Mar; 100(10):e25121. PubMed ID: 33725910
[TBL] [Abstract][Full Text] [Related]
29. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
Standl E; Stevens SR; Lokhnygina Y; Bethel MA; Buse JB; Gustavson SM; Maggioni AP; Mentz RJ; Hernandez AF; Holman RR;
Diabetes Care; 2020 Mar; 43(3):643-652. PubMed ID: 31882409
[TBL] [Abstract][Full Text] [Related]
30. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
[TBL] [Abstract][Full Text] [Related]
31. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; De Grauw WJ
Cochrane Database Syst Rev; 2006 Oct; (4):CD005061. PubMed ID: 17054235
[TBL] [Abstract][Full Text] [Related]
32. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.
Everett BM; Cornel JH; Lainscak M; Anker SD; Abbate A; Thuren T; Libby P; Glynn RJ; Ridker PM
Circulation; 2019 Mar; 139(10):1289-1299. PubMed ID: 30586730
[TBL] [Abstract][Full Text] [Related]
33. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Diabetologia; 2004 Jun; 47(6):969-75; discussion 976-7. PubMed ID: 15164169
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes.
Coleman RL; Scott CAB; Lang Z; Bethel MA; Tuomilehto J; Holman RR
Cardiovasc Diabetol; 2019 Oct; 18(1):135. PubMed ID: 31623625
[TBL] [Abstract][Full Text] [Related]
35. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
36. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study.
Anand SS; Dagenais GR; Mohan V; Diaz R; Probstfield J; Freeman R; Shaw J; Lanas F; Avezum A; Budaj A; Jung H; Desai D; Bosch J; Yusuf S; Gerstein HC;
Eur J Prev Cardiol; 2012 Aug; 19(4):755-64. PubMed ID: 21551215
[TBL] [Abstract][Full Text] [Related]
37. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
Shavadia JS; Zheng Y; Green JB; Armstrong PW; Westerhout CM; McGuire DK; Cornel JH; Holman RR; Peterson ED
Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
[TBL] [Abstract][Full Text] [Related]
38. Relation of obesity to heart failure hospitalization and cardiovascular events in persons with stable coronary heart disease (from the Heart and Soul Study).
Spies C; Farzaneh-Far R; Na B; Kanaya A; Schiller NB; Whooley MA
Am J Cardiol; 2009 Oct; 104(7):883-9. PubMed ID: 19766751
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.
Quilici S; Chancellor J; Maclaine G; McGuire A; Andersson D; Chiasson JL
Int J Clin Pract; 2005 Oct; 59(10):1143-52. PubMed ID: 16178980
[TBL] [Abstract][Full Text] [Related]
40. Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial.
Verma S; Leiter LA; Zinman B; Sharma A; Mattheus M; Fitchett D; George J; Ofstad AP; Kosiborod MN; Wanner C; Inzucchi SE
ESC Heart Fail; 2021 Aug; 8(4):2603-2607. PubMed ID: 34132492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
